# Vaxart clinical trials: 23 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials with Vaxart as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Vaxart: 23 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/vaxart

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 28, 2025 | NCT07254728 | A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants | Vaxart | Phase 1 | Completed | Norovirus Infections | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07254728) |
| April 25, 2025 | NCT06944717 | A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old | Vaxart | Phase 1 | Completed | Norovirus Infections | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06944717) |
| November 4, 2024 | NCT06672055 | A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults... | Vaxart | Phase 2 | Active not recruiting | SARS-CoV2, COVID-19 | 5,485 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06672055) |
| November 25, 2022 | NCT05626803 | A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers | Vaxart | Phase 2 | Completed | Norovirus Infections | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05626803) |
| January 28, 2022 | NCT05213728 | A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet... | Vaxart | Phase 1 | Completed | Norovirus Infections | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05213728) |
| January 27, 2022 | NCT05212168 | Norovirus Challenge Study | Vaxart | Phase 1/2 | Completed | Norovirus Infections | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05212168) |
| October 5, 2021 | NCT05067933 | A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine | Vaxart | Phase 2 | Terminated | COVID-19 | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05067933) |
| May 6, 2021 | NCT04875676 | Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines | Vaxart | Phase 1/2 | Completed | Norovirus Infections | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04875676) |
| April 22, 2021 | NCT04854746 | Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine | Vaxart | Phase 1 | Completed | Norovirus Infections | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04854746) |
| September 24, 2020 | NCT04563702 | Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost... | Vaxart | Phase 1 | Completed | Covid19 | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04563702) |
| April 1, 2019 | NCT03897309 | Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines | Vaxart | Phase 1 | Completed | Norovirus Infection | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03897309) |
| April 24, 2017 | NCT03125473 | Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers | Vaxart | Phase 1 | Completed | Norovirus Gastroenteritis | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03125473) |
| April 20, 2017 | NCT03121339 | Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults | Vaxart | Phase 1 | Completed | Seasonal Influenza Preventative Vaccine Pharmacodynamics | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03121339) |
| January 18, 2017 | NCT03024177 | A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection | Vaxart | Phase 2 | Withdrawn | Rhinovirus, Upper Respiratory Tract Infection | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03024177) |
| September 28, 2016 | NCT02918006 | A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine | Vaxart | Phase 2 | Completed | Influenza | 179 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02918006) |
| August 16, 2016 | NCT02868073 | Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine | Vaxart | Phase 1 | Completed | Norovirus Gastroenteritis | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02868073) |
| July 13, 2016 | NCT02830932 | Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f) | Vaxart | Phase 1 | Completed | Respiratory Syncytial Virus (RSV) | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02830932) |
| March 31, 2016 | NCT02724254 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to... | Vaxart | Phase 2 | Completed | Condyloma | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02724254) |
| September 11, 2015 | NCT02547792 | Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults | Vaxart | Phase 1 | Completed | Seasonal Influenza B | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02547792) |
| January 4, 2013 | NCT01761123 | Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum | Vaxart | Phase 1 | Completed | Seasonal Influenza | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01761123) |
| October 2, 2012 | NCT01698060 | Immunogenicity of ND1.1 by Delivery Directly to the Ileum | Vaxart | Phase 1 | Completed | Avian Influenza | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01698060) |
| September 19, 2012 | NCT01688297 | Safety Study of an Oral Vaccine to Prevent Seasonal Influenza | Vaxart | Phase 1 | Completed | Influenza | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01688297) |
| April 14, 2011 | NCT01335347 | Safety Study of an Oral Vaccine to Prevent Avian Influenza | Vaxart | Phase 1 | Completed | Avian Influenza, Bird Flu | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01335347) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 15 |
| Phase 1/2 | 2 |
| Phase 2 | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| Withdrawn | 1 |
| Terminated | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Caliciviridae Infections | 8 |
| COVID-19 | 3 |
| Influenza, Human | 3 |
| Influenza in Birds | 2 |
| Condylomata Acuminata | 1 |
| Sexually Transmitted Diseases | 1 |
| Papillomavirus Infections | 1 |
| Virus Diseases | 1 |
| Respiratory Tract Infections | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Cosmetic surgery practices in the United States](https://specstream.ai/data/businesses/cosmetic-surgery-practices/united-states)
- [Mattress manufacturing companies in the United States](https://specstream.ai/data/businesses/mattress-manufacturing-companies/united-states)
- [Truck rental companies in the United States](https://specstream.ai/data/businesses/truck-rental-companies/united-states)
- [Demolition contractors in the United States](https://specstream.ai/data/businesses/demolition-contractors/united-states)
- [Merchandising companies in the United States](https://specstream.ai/data/businesses/merchandising-companies/united-states)
- [Vehicle parts manufacturers in the United States](https://specstream.ai/data/businesses/vehicle-parts-manufacturers/united-states)
